Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 15/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 13/20 | 0.52 |
| ▸ | GSK3B | P49841 | 13/20 | 0.49 |
| ▸ | SRC | P12931 | 10/20 | 0.49 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24668011 | 0.94 | AURKA (0.53) | AURKAAURKBGSK3BSRCEIF2AK2 | |
| SCHEMBL22701711 | 0.93 | AURKA (0.52) | AURKAAURKBGSK3BSRCEIF2AK2 | |
| SCHEMBL25875753 | 0.82 | RET (0.46) | AURKAAURKBJAK2 | |
| SCHEMBL25876129 | 0.81 | PLK4 (0.46) | JAK2 | |
| SCHEMBL18789261 | 0.81 | RET (0.56) | AURKAAURKBJAK2 | |
| SCHEMBL28411559 | 0.80 | RET (0.44) | AURKAAURKBGSK3BSRCJAK2 | |
| SCHEMBL30250267 | 0.80 | RET (0.44) | AURKAAURKBGSK3BSRCJAK2 | |
| SCHEMBL25875939 | 0.80 | RET (0.44) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL25876350 | 0.80 | RET (0.43) | AURKAAURKBAURKCJAK2JAK1 | |
| SCHEMBL25876081 | 0.79 | RET (0.43) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220233513-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2022-07-28 | — | — | US | disclosed |
| WO-2020233641-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | 浙江同源康医药股份有限公司 (CN) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233513-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | AURKA 649/4885AURKB 699/4885GSK3B 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.